Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.56 USD | +10.43% | -1.07% | -45.11% |
05-09 | Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating | MT |
05-09 | Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.11% | 414M | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- Editas Medicine Enters Licensing Deal With Vertex Pharmaceuticals for Cas9